Is Biomea Fusion Stock a Good Investment?
Biomea Fusion Investment Advice | BMEA |
- Examine Biomea Fusion's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biomea Fusion's leadership team and their track record. Good management can help Biomea Fusion navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biomea Fusion's business and its evolving consumer preferences.
- Compare Biomea Fusion's performance and market position to its competitors. Analyze how Biomea Fusion is positioned in terms of product offerings, innovation, and market share.
- Check if Biomea Fusion pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biomea Fusion's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biomea Fusion stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biomea Fusion is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Biomea Fusion Stock
Researching Biomea Fusion's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biomea Fusion recorded a loss per share of 4.01. The entity had not issued any dividends in recent years.
To determine if Biomea Fusion is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomea Fusion's research are outlined below:
| Biomea Fusion generated a negative expected return over the last 90 days | |
| Biomea Fusion has high historical volatility and very poor performance | |
| Net Loss for the year was (117.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomea Fusion currently holds about 149.63 M in cash with (96.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 100000 shares by A2a Pharmaceuticals, Inc. of Biomea Fusion at 33.9931 subject to Rule 16b-3 |
Biomea Fusion Quarterly Cost Of Revenue |
|
Biomea Fusion uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biomea Fusion. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomea Fusion's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Biomea Fusion's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Biomea Fusion's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-03 | 2021-09-30 | -0.39 | -0.43 | -0.04 | 10 | ||
2022-02-28 | 2021-12-31 | -0.45 | -0.51 | -0.06 | 13 | ||
2024-05-02 | 2024-03-31 | -0.99 | -1.09 | -0.1 | 10 | ||
2024-01-09 | 2023-12-31 | -0.85 | -0.98 | -0.13 | 15 | ||
2022-11-07 | 2022-09-30 | -0.65 | -0.78 | -0.13 | 20 | ||
2021-08-11 | 2021-06-30 | -0.2 | -0.33 | -0.13 | 65 | ||
2023-05-02 | 2023-03-31 | -0.81 | -0.98 | -0.17 | 20 | ||
2023-07-31 | 2023-06-30 | -0.88 | -0.7 | 0.18 | 20 |
Biomea Fusion Target Price Consensus
Biomea target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Biomea Fusion's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most Biomea analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Biomea stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Biomea Fusion, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBiomea Fusion Target Price Projection
Biomea Fusion's current and average target prices are 2.87 and 40.56, respectively. The current price of Biomea Fusion is the price at which Biomea Fusion is currently trading. On the other hand, Biomea Fusion's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Biomea Fusion Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Biomea Fusion Target Price
Biomea Fusion Analyst Ratings
Biomea Fusion's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Biomea Fusion stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Biomea Fusion's financials, market performance, and future outlook by experienced professionals. Biomea Fusion's historical ratings below, therefore, can serve as a valuable tool for investors.Know Biomea Fusion's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomea Fusion is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomea Fusion backward and forwards among themselves. Biomea Fusion's institutional investor refers to the entity that pools money to purchase Biomea Fusion's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Advisers, Llc | 2024-12-31 | 459.5 K | Renaissance Technologies Corp | 2024-12-31 | 343.7 K | Northern Trust Corp | 2024-12-31 | 322.6 K | Woodline Partners Lp | 2024-12-31 | 240.8 K | Walleye Trading Advisors, Llc | 2024-12-31 | 235.7 K | Charles Schwab Investment Management Inc | 2024-12-31 | 200.4 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 197.5 K | Rock Springs Capital Management Lp | 2024-12-31 | 181.1 K | Deutsche Bank Ag | 2024-12-31 | 180.3 K | Fmr Inc | 2024-12-31 | 5.4 M | Cormorant Asset Management, Llc | 2024-12-31 | 3.6 M |
Biomea Fusion's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 100.38 M.Market Cap |
|
Biomea Fusion's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.82) | (0.78) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.80) | (0.76) |
Determining Biomea Fusion's profitability involves analyzing its financial statements and using various financial metrics to determine if Biomea Fusion is a good buy. For example, gross profit margin measures Biomea Fusion's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biomea Fusion's profitability and make more informed investment decisions.
Please note, the presentation of Biomea Fusion's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomea Fusion's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomea Fusion's management manipulating its earnings.
Evaluate Biomea Fusion's management efficiency
Biomea Fusion has return on total asset (ROA) of (0.5638) % which means that it has lost $0.5638 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0451) %, meaning that it created substantial loss on money invested by shareholders. Biomea Fusion's management efficiency ratios could be used to measure how well Biomea Fusion manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.55. The current year's Return On Capital Employed is expected to grow to -0.78. At present, Biomea Fusion's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 127.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.47 | 2.66 | |
| Tangible Book Value Per Share | 4.47 | 2.67 | |
| Enterprise Value Over EBITDA | (2.37) | (2.49) | |
| Price Book Value Ratio | 2.63 | 2.77 | |
| Enterprise Value Multiple | (2.37) | (2.49) | |
| Price Fair Value | 2.63 | 2.77 | |
| Enterprise Value | 122.1 M | 128.2 M |
Biomea Fusion benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta (0.28) |
Basic technical analysis of Biomea Stock
As of the 21st of March, Biomea Fusion shows the Risk Adjusted Performance of (0.17), mean deviation of 3.9, and Standard Deviation of 5.37. Biomea Fusion technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biomea Fusion's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomea Fusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomea Fusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomea Fusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biomea Fusion's Outstanding Corporate Bonds
Biomea Fusion issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomea Fusion uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomea bonds can be classified according to their maturity, which is the date when Biomea Fusion has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Biomea Fusion's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Biomea Fusion's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | 2.75 | |||
| Mean Deviation | 3.9 | |||
| Coefficient Of Variation | (502.10) | |||
| Standard Deviation | 5.37 | |||
| Variance | 28.86 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.11) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | 2.74 | |||
| Maximum Drawdown | 24.41 | |||
| Value At Risk | (8.98) | |||
| Potential Upside | 6.48 | |||
| Skewness | (1.18) | |||
| Kurtosis | 2.63 |
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | 2.75 | |||
| Mean Deviation | 3.9 | |||
| Coefficient Of Variation | (502.10) | |||
| Standard Deviation | 5.37 | |||
| Variance | 28.86 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.11) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | 2.74 | |||
| Maximum Drawdown | 24.41 | |||
| Value At Risk | (8.98) | |||
| Potential Upside | 6.48 | |||
| Skewness | (1.18) | |||
| Kurtosis | 2.63 |
Consider Biomea Fusion's intraday indicators
Biomea Fusion intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biomea Fusion stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Biomea Fusion Corporate Filings
8K | 28th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 6th of January 2025 Other Reports | ViewVerify | |
F4 | 2nd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Biomea Stock media impact
Far too much social signal, news, headlines, and media speculation about Biomea Fusion that are available to investors today. That information is available publicly through Biomea media outlets and privately through word of mouth or via Biomea internal channels. However, regardless of the origin, that massive amount of Biomea data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biomea Fusion news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomea Fusion relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomea Fusion's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomea Fusion alpha.
Biomea Fusion Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Biomea Fusion can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biomea Fusion Corporate Management
| Juan MD | Chief Officer | Profile | |
| Caroline Dupont | Senior Contracts | Profile | |
| Alex Cacovean | Vice Sciences | Profile | |
| Naomi Cretcher | Chief Officer | Profile | |
| Heow Tan | Chief Officer | Profile | |
| Stephan MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Biomea Fusion's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.